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Burden of lipohypertrophy among insulin dependent diabetes mellitus patients in China: An 




Advisor: William T. Gallo 
Background 
Diabetes is a global epidemic and with an aging population accompanied by rapid 
urbanization China ranks highest in disease prevalence and associated burden.  Independent of 
diabetes type, insulin is an eventual and costly requirement for disease management.  The 
consequences of insulin administration however are poorly understood.  Lipohypertrophy (LH) is 
one such consequence.  It is hypothesized that method of insulin delivery and poor delivery 
technique are significant risk factors for this condition which is believed to alter insulin 
pharmacodynamics.  Subsequently, insulin pen needles are a critical component of care however 
access to pen needles varies across China.   
Objective 
The objective of this study is to characterize the insulin injecting population in China, 
determine the prevalence of LH and highlight attributable risk factors.  This research is also 
intended to explore the relationship between pen needle reimbursement policy, injection 






A cross-sectional examination was conducted among 401 insulin users with Type 1 or 
Type 2 diabetes treated in outpatient endocrinology units of four large tertiary care hospitals in 
Nanjing, Chongqing, Beijing and Zhengzhou.  Eligible participants were between the ages of 18-
80 and taking insulin for a duration of greater than 1 year.  Demographics, medical history 
including HbA1c, healthcare resource utilization (HRU), out-of-pocket costs, insurance and PN 
reimbursement status were surveyed.  LH prevalence was clinically confirmed at the time of 
examination.  Differences between those with and without LH were evaluated by Student’s t-test 
or Wilcoxon rank sum.  Unit costs were assigned to insulin and healthcare HRU and compared 
using descriptive statistics and multivariate regression models.  
Results 
A total of 403 patients provided informed consent of which 401 completed the clinical 
module of the survey and 400 completed the HRU section.  Half the study population was male 
(49.9%) with an average age of 59.6 year and BMI of 25.4 kg/m2.  Most patients in this study 
were diagnosed with Type 2 diabetes (93%) and had diabetes for an average duration of 11.8 
years and using insulin for 5.8 years (range 1-29.3 years).  Prevalence of LH in this population 
was established to be 53.1%.   
More than half the study population reported at least one diabetes related outpatient (OP) 
visit (62.7%) and 14.4% of the sample had at least one hospital stay in the past 6 months.  The 
average number of diabetes related OP visits and hospital stays per patient was 2.55 (SD 2.55) 
and 0.177 (SD 0.516) respectively.  The average daily insulin dose was 33.95 (SD 18.41) with 
patients reporting a range from 6 -118 units per day.  Nearly 100% of study participants had 




 LH prevalence was observed to be 18.6% higher in those without PN reimbursement 
(59.3% vs. 40.7%, p=0.0007).  LH patients also exhibited higher HbA1c (8.2 vs 7.7%), insulin 
consumption (11U), median PN reuse (12 vs. 7 times per needle, p<0.0001), and costs (6-month 
insulin costs 1591 vs. 1328 RMB, p=0.0025; 6-month total HRU 6433 vs. 4432 RMB, 
p<0.0001).  Injection site rotation and PN reuse frequency were both identified as risk factors for 
LH along with BMI and reimbursement.  Incorrect injection site rotation had an odds ratio of 8.4 
(p≤0.001).   
Total cost of excess insulin consumption adjusted for adherence was estimated to be $313 
million 2015 USD. 
Conclusions 
LH widespread complication among the insulin injecting diabetic population in China.  
LH is associated with higher insulin consumption and worse glycemic control.  Insulin users 
without PN reimbursement may pose a greater economic burden to China compared to those 
with PN reimbursement.  Injection site rotation and reduction in needle reuse may limit the 
development and impact of this complication.  Furthermore, broader coverage for PN may 
reduce clinical and economic burden on the patient and healthcare system while improving 
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SECTION 1: INTRODUCTION 
Health care access and chronic disease management 
Access to healthcare has long been implicated as a reason for poor utilization of health 
services.  The difference between these two concepts stems from the belief that appropriate 
access to care implies equity, or the lack of “systematic differences” between patients with or 
without access, whereas utilization refers to the consumption of services, such as 
outpatient/inpatient visits or prescriptions filled.  Essentially, access encompasses both 
unmodifiable (e.g. race/ethnicity, age, gender) and modifiable (e.g. income, education level, 
insurance status, neighborhood/ community factors) elements, which can either facilitate or 
preclude individuals’ utilization of health services.  The Institute of Medicine’s (IOM) definition 
of healthcare access—” the timely use of personal health services to achieve the best possible 
health outcomes”—makes clear that patient utilization and outcomes are inextricably linked to 
healthcare access1-3. 
The principal objective of a healthcare system is to foster or sustain individual and 
population health. For individuals who have already developed a noncommunicable (or chronic) 
disease, studies have reported that the delivery of disease self-management programs and health 
education have positively affected health and economic outcomes4. Yet, other factors may 
influence the effectiveness of these programs, including demographic attributes, health literacy 
and insurance and access to care. A systematic review of health literacy and health outcomes 
demonstrated a strong association between low health literacy and numerous adverse outcomes, 
including high health resource utilization, fewer screenings, poor adherence to medications and 
poorer overall health and health outcomes5.  Health insurance, a key factor in access to care (i.e., 




to be protective among patients with chronic disease, with studies’ reporting that insured patients 
and those who hold additional drug coverage are more likely to have better health outcomes than 
those who lack such coverage6,7. 
Preventative care is a critical element in the maintenance of well-being, particularly 
individuals at pronounced risk for chronic disease.  The logic is intuitive.  In seeking 
preventative care, patients at risk for chronic conditions will be diagnosed and treated promptly, 
which establishes the foundation of disease management.  Quite the opposite, patients who do 
not seek preventative healthcare services will be diagnosed much later in the disease process, 
raising the potential for more acute care and lower likelihood of successful clinical or self-
management2,8. Late-stage disease activity for unmanaged patients often presents with greater 
symptom severity and worsened functionality than among patients who are diagnosed and seek 
treatment at earlier stages of disease.  In the cases where financial burden and access to care 
preclude earlier management, greater outcome severity ensues.  In vascular disease, 
socioeconomic disadvantage has been correlated with greater need for surgical procedures, and 
may lead to a higher likelihood of limb amputation, which is indicative of end-stage disease9, 10. 
In dyslipidemia, cardiovascular disease, and diabetes, lack of insurance coverage and 
underutilization of health services have been associated with underuse of services and poorer 
health outcomes11-13.  
 While the scientific literature has established a relationship between access to healthcare 
and disease severity, the mechanism by which these two domains are linked has yet to be clearly 
established. One proposed mechanism is that reduced access to care delays disease management, 
which then leads to greater severity of disease; this translates to worsened outcomes in the long-




of time to produce an effect. Another possibility is that health education modifies the relationship 
between access to care and disease severity.  Despite the mechanism, the multiple burdens of 
suboptimal healthcare access, both direct and indirect, are primarily borne by the patient.  When 
aggregated, access problems are costly depletors of economic value and social value7. 
Diabetes 
Diabetes is a condition of the pancreas that occurs as a result of poor insulin production 
or insulin resistance. The insulin hormone produced in the pancreas is the primary transport 
mechanism for glucose in the blood to be moved to cells where it can be further broken down 
and utilized.  Thus, a diagnostic marker for this disease is the presence of excess glucose in the 
blood.  If elevated glucose levels are left unaddressed, a patient is at risk for serious 
comorbidities, including cardiovascular disease, kidney damage, nerve damage and eye disease.  
Secondary to these conditions are amputation and blindness.  Although diabetes and the 
underlying beta cell damage in the pancreas cannot be reversed, effective management of the 
condition can delay or entirely prevent complications.   
There are three main types of diabetes including Type 1, Type 2 and gestational.  Type 1 
diabetes is believed to be caused by an autoimmune response that ultimately incapacitates 
insulin-producing beta cell function.  This condition most often occurs during childhood or 
adolescence, and insulin therapy is compulsory for survival.  Symptoms may include abnormal 
thirst, frequent urination, fatigue, hunger, sudden weight loss, bed wetting and blurred vision14,15.   
Type 2 diabetes is the most prevalent type, and accounts for 90% of the disease burden 
worldwide. Type 2 diabetes is characterized by insulin resistance whereby insulin is still 
produced (although inadequately), however the body is unable to effectively utilize it, leading to 




older adults. Nevertheless, adolescent prevalence of the disease is on the rise, consistent with 
increases in childhood obesity. Due to the lack of physical symptoms associated with Type 2 
diabetes, the number of undiagnosed patients is also believed to be significant.  Patients may, 
moreover, feel less urgency to manage the condition. Delaying treatment, however, results in the 
same complications as Type 1 diabetes over the longer term. The causes of Type 2 diabetes are 
not known, however there are strong linkages with a combination of genetic and modifiable risk 
factors (Figure 1.1)14,15. 














 Gestational diabetes, also referred to as hyperglycemia in pregnancy, is a condition that 
most commonly afflicts women during the second or third trimester of pregnancy.  In this case, 
insulin resistance occurs due to the interference of hormones produced by the placenta.  




developing gestational diabetes during future pregnancies.  In addition, approximately 50% of 
women with gestational diabetes develop Type 2 diabetes within 5-10 years.  Gestational 
diabetes can lead to high blood pressure, larger birth weights, and in some cases, difficult 
deliveries.  The condition is diagnosed using an oral glucose tolerance test14,15.   
Diabetes Management 
The goal of diabetes management is to regulate the body’s insulin response in order to 
optimize glucose utilization and avoid associated complications, such as renal failure, 
retinopathy, neuropathy or amputation.  Proper diabetes management may also reduce the risk of 
cardiovascular disease in at-risk patients.  Lifestyle interventions are normally the first line of 
defense for individuals with pre- or early onset- diabetes.  These interventions may include 
modifications in diet and physical activity in addition to health education for patients and 
caregivers.  When such interventions are no longer independently adequate, health practitioners 
turn to pharmacotherapies, specifically oral antidiabetic agents (OAD).  The first-line OAD for 
patients with Type 2 diabetes is metformin, which works to improve the body’s response to its 
own insulin while reducing glucose production in the liver.  OADs are not curative, and are 
intended only to slow the progression of diabetes.  When metformin is no longer effective in 
maintaining glycemic control, second-line agents, such as sulfonylureas, glinides, 
thiazolidinediones, and dipeptidyl peptidase 4 inhibitors, are typically added for additional 
control.  Eventually, beta cell dysfunction in all diabetic patients reaches a point where insulin or 
insulin analogs become mandatory for blood glucose management to avoid serious complications 




Burden of Total Diabetes 
Diabetes is one of the World Health Organization’s top 10 noncommunicable diseases 
and is responsible for 4% of all noncommunicable disease-related deaths17.  In addition to its 
critical mortality implications, diabetes has substantial morbidity and economic ramifications, 
further validating this condition as a serious global public health concern.  In 2015, the 
International Diabetes Federation (IDF) estimated that 415 million people (9.1%) worldwide had 
diabetes, reflecting nearly a tripling in disease prevalence in a period of two decades (Figure 
1.1).  The changing demographic and socioeconomic patterns around the world are expected to 
further increase the number of people who are at risk for diabetes and who eventually develop 
the disease.  As the population ages, and such risk factors as obesity, high cholesterol and 
hypertension continue to rise at an equally alarming pace, the IDF has conservatively projected 
the global prevalence of the disease to exceed 640 million individuals by 2040 (Figure 1.2)18.   
Figure 1.2. Prevalence of Diabetes 1965-204018-26  
 
*Projected prevalence 































































The prevalence of diabetes is noted to be disproportionate among those living in middle- 
and high-income countries, and 75% of all people with diabetes were found to be living in low-
to-middle income countries.  Over half of the global diabetic population is concentrated in 
South-East Asia and the Western Pacific region, with China and India leading the way with the 
most number of adults living with diabetes.  China and India also spend the least per capita on 
management of the disease18,14.     
Like many chronic conditions, diabetes prevalence and incidence can be triggered or 
exacerbated by a variety of influencers.  Research has substantiated that the most influential 
behaviors in the development of Type 2 diabetes are those stimulated by urbanization, whose 
potential mediating effects include changes in nutrition, decreased physical activity and more 
sedentary lifestyles.  Furthermore, randomized clinical trials from have demonstrated that 
modification of these behaviors can avoid or delay the onset of Type 2 diabetes27-29,14.  
Once diagnosed, diabetes requires a great deal of clinical management to prevent disease 
progression and development of commonly associated comorbidities.  This management includes 
regular lab tests, physical examinations focusing on healthy eye and foot care, regular 
vaccinations, and cholesterol management30. There is also evidence to support the efficacy and 
economic benefits of secondary prevention (e.g., controlling glucose, lipid, and blood pressure 
levels) and tertiary prevention (e.g., screening and treating early for early diabetes 
complications).  Unfortunately, these scientifically and economically justified prevention 
programs are not often effectively used in clinical practice, often due to the lack of patient access 






Economic Burden of Diabetes  
Without proper management of the condition the global population will be subject to 
deteriorating health while faced with the pressures of increasing healthcare expenditures.  Since 
the International Diabetes Federation started tracking global diabetes-related healthcare 
expenditures in 2006, there has been a threefold increase in spending (Figure 1.3).  In the most 
recent assessment of healthcare expenditures associated with diabetes, the IDF estimates diabetes 
to cost in excess of $727 billion USD globally in 2017.  When expanding the age groups for this 
estimate to 18-99 years, this cost jumps to $850 billion.  At the country level, the highest 
expenditures were observed in the US ($348 billion) followed by China ($110 billion).  
However, China falls off the top 10 list when calculating diabetes expenditure per capita, leaving 
the US in the number one spot ($11,638/person).  Diabetics between the ages of 60-69 pose the 
largest economic burden, with an expenditure of ($127 billion), followed by those ages 70-79 
($86 billion).  This burden is largely due to the nature of the progression of the condition and 
incidence of diabetes-related comorbidities later in life.   








































When compared to the general population, people with diabetes use a greater amount of 
healthcare resources, including in- and out-patient services, medications, and long-term care.  
They have a higher probability of being hospitalized or requiring emergency care, which are 
contributors to the magnitude of healthcare dollars spent on this population.  What is not well 
summarized in the global literature is the expanse of indirect costs associated with this 
population.  Indirect expenditures may include transportation expenses to seek care, 
accommodation expenses, social or workplace productivity loss, nutritional expenses or 
opportunity cost due to premature death or disability34. A 2017 report estimated that the 
inclusion of indirect costs, in addition to those associated with diabetes-related complications 
such as cardiovascular disease, raised the total cost of diabetes to $1.3 trillion USD14. 
Although the projected number of individuals with diabetes is expected to grow to 629 
million people in 2045, the related healthcare expenditures are only expected to increase 7%.  
This is due to the fact that growth in diabetes prevalence is expected to occur in low- and middle-
income countries, which spend fewer healthcare dollars on diabetes management today14,18. 
Diabetes in China 
Thanks to economic prosperity and a long-term vision for national development, China is 
rising to be a global economic competitor with parallel success in the form of longer life 
expectancy and nearly full healthcare coverage for its population.  At the same time, China has 
come to face accompanying challenges, including escalating healthcare costs and growing 
inequity in distribution of health resources between urban and rural populations.  Although great 
progress has been made in moving a majority of those who meet the World Health 
Organization’s definition of poverty to a higher economic status, much of China’s population 




2053, China is expected to have 487 million senior citizens, with over 70% of the population 
living in urban communities.  This shift in demographics—accompanied by rapid urbanization 
and rising income inequality—makes the problem of chronic disease prevalence and burden of 
out-of-pocket expenditures to manage these conditions substantially more prevalent35.  
Figure 1.4. Income and Poverty in China36 
 
 
As previously mentioned, China ranks number one in diabetes prevalence.  A national 
survey published in JAMA found diabetes prevalence in China to be 10.9%.  This figure, 
substantiated by the International Diabetes Federation, translates to 114.4 million people37,14. 
This prevalence is 16 times higher than that reported in the first Chinese national health survey 




implying that an additional 374.6 million people could be at high risk for developing diabetes if 
unaddressed37. China also has the world’s most diabetics older than 65, currently 34.1 million 
individuals, and is expected to balloon to 67.7 million by 204514.  In China’s younger population, 
Type 2 prevalence nearly doubled between 2008 and 2013 (Figure 1.5).  This cohort also had 
high A1C and higher rates of complications over time than those with late onset disease16. 
Although there is evidence of variance in genetic risk among ethnicities within China, lifestyle 
changes accompanying economic growth, coupled with poor health education and an aging 
population, have been cited as key contributors to the rise in diabetes prevalence37,39.  
Figure 1.5. Prevalence of Diabetes and prediabetes among Chinese individuals <40 years of 
age16  
 
A similar upward trend is seen in diabetes-related healthcare expenditures in China.  
China spends a total of $110 billion USD annually on diabetes, accounting for over 50% of the 
diabetes-related healthcare expenditures in the Western Pacific region14. A study conducted in 
2017 reported that age- and sex-adjusted spending for people in China living with diabetes is 3.4 
times more than those without disease40. It has been noted, however, that only 32.2% of patients 




than half (49.2%) were achieving their glycemic goals.  These trends also vary within rural vs 
urban residence and associated access to care37,16.   
 The majority of China’s population has some health care coverage under one of China’s 
three main insurance offerings: Urban Employee Basic Medical Insurance (UEBMI), Urban 
Residence Basic Medical Insurance (URBMI) and Rural New Cooperative Medical Schemes 
(RNCMS).  UEBMI is mainly funded through employee payroll tax, whereas URBMI and 
RNCMS are both government subsidized.  Although UEBMI is a comprehensive coverage plan, 
most citizens are insured under URBMI or RNCMS, which limits coverage to inpatient service 
and some pre-specified outpatient services.  This makes both prevention and day-to-day 
management of chronic conditions a personal financial burden for many Chinese.  Individuals 
insured with UEBMI have been noted to have higher expenditures than both URBMI and 
RNCMS, however this may be linked to not only expanse of coverage, but also where 
individuals are seeking care40,41.   
Even within these insurance schemes, there is further variability in coverage of 
procedures, drugs and devices within and between provinces and cities in China.  This variability 
is due in part to China’s complex coverage, payment and procurement process.  In the case of 
medical devices for example, technologies are first classified by the National Development and 
Reform Commission as implantable or consumable.  Once a device has been classified, 
manufactures can apply for coverage at the provincial level by filing individual applications with 
the local Ministries of Health.  Each provincial ministry, and accompanying pricing bureau, sets 
a maximum price for the product, which then triggers further local assessment of budget impact 
and fit within provincial insurance schemes.  If a product is listed at the provincial level, then 




available budgets vary by province and city, it is possible that adjacent province or cities may 
have significantly differing coverage for health technologies42.    
  China has three tiers of hospitals, including tier 3 (tertiary), tier 2 (secondary) and tier 1 
(primary or community health centers).  At the extremes, tertiary hospitals tend to be large, 
academically affiliated institutions set in urban areas, whereas community health centers are 
generally more broadly distributed.  The three tiers differ in function (i.e., types of procedures), 
technology, quality of care and scientific management.  A survey conducted to assess 
management of noncommunicable disease in China found that significantly more urban residents 
received diabetes treatment than rural residents (41.8% vs 27.6%)16. Expenditures for high-
income urban residents also tend to be higher.  Income has been correlated with longer-term 
therapy strategies, as it may be able to bridge out-of-pocket coverage gaps34.  
Recognizing the local burden and global trends in containing noncommunicable diseases 
such as diabetes, China has taken numerous legislative steps to address environmental risks, such 
as tobacco control and expansion of healthcare access to rural communities and underserved 
communities (i.e. URBMI and RNCMS).  Most recently, China has proposed the “Medium-to-
Long Term Plan of China for the Prevention and Treatment of Chronic Diseases (2017–2025),” 
which includes 8 specific strategic measures (Table 1.1)43.  With regard to diabetes, much of the 
country’s focus has been on monitoring and surveillance programs41. 
Table 1.1. Strategic Measures of China's Medium-to-Long Term Plan for the Prevention 
and Treatment of Chronic Diseases 
Strategy Goal 
Promote health education Boost national healthy quality 
Enforce early diagnosis and 
treatment 




Reinforce standardized treatment Improve therapeutic effects 
Facilitate the cooperation between 
medical treatment and prevention 
Achieve comprehensive healthcare management 
Refine medical security policies Effectively reduce the public's medical burden 
Control risk factors  Construct a healthy supportive environment 
Arranging social resources in an 
innovative way  
Drive the development of the healthcare service 
industry 
Bolster technological support  Enhance monitoring, evaluation, and 
innovation in research and development 
  
In the World Health Organization’s first Global Report on Diabetes (2016), the Director 
General remarked “…in many settings the lack of effective policies to create supportive 
environments for healthy lifestyles and the lack of access to quality health care means that the 
prevention and treatment of diabetes, particularly for people of modest means, are not being 
pursued.”  If unmanaged, diabetes can be life-threatening and place an enormous economic 
burden on individuals and health systems.  In end-stage diabetes, insulin replacement becomes a 
compulsory part of disease management, so that when access to care is impeded, patients are 
rendered perilously vulnerable44.    
Although substantial research has been, and continues to be, conducted on healthcare 
policy and pharmacotherapy for diabetes management and glucose control, to date little attention 
has been paid to secondary factors, such as drug delivery technique and associated complications 
that may help optimize efforts to reach glycemic control. 
Role of lipohypertrophy in diabetes management 
In the past, limited attention was given to the importance of insulin-injection practices in 




injection-related complications, specifically Lipohypertrophy (LH).  LH is an avoidable clinical 
complication affecting insulin injecting diabetes patients.  It is a condition that is believed to 
result from repetitive use of an insulin injection site or lack of injection site rotation.  LH 
presents as a firm lump, or raised mass, which results from the abnormal accumulation of fat at 
the injection site.  Aside from the potential disfigurement caused by the condition, LH tissue 
impedes insulin absorption, which can lead to significant glycemic variability45.  In 2016, the 
first temporal relationship was established between injecting into a LH lesion and glycemic 
variability in a controlled setting46.   
The injection technique questionnaire (ITQ), conducted among 13,289 insulin-injecting 
patients from 423 centers in 42 countries between the years of 2014 and 2015, demonstrates that 
LH is underdiagnosed.  The survey also indicates that individuals with LH used more insulin per 
day and had higher A1c levels than insulin injectors without indication of LH.  This group of 
patients (i.e., patients with LH) also had a higher prevalence of hypoglycemia and recorded 
glucose variability.  In addition to poor detection, the ITQ survey indicated that almost half the 
respondents reuse needles for reasons of convenience and cost.  The practice of needle reuse was 
correlated with LH and glycemic variability47.  
The findings of the ITQ were not directionally dissimilar to other literature on this 
subject, however, LH prevalence data has shown to vary across regions (see Section 2).  The 
clinical implications of LH are broad.  Nearly 40% of patients with LH experienced unexplained 
hypoglycemia and nearly half experienced glycemic variability.  Comparatively, fewer than 7% 
of the general insulin injecting population experienced either complication48.  Glycemic 
variability, or swings in blood glucose levels, has been associated with various types of 




cardiovascular health in high-risk Type 2 diabetes patients.  It is important to note that although 
these correlations have been observed in both prospective and retrospective research, 
replicability of the results remains an issue.  There are a number of studies that have not been 
able to demonstrate the same strength in relationships.  A conclusion that the research does draw 
is that the nervous system may be vulnerable to regular fluctuations in blood glucose49.  
Although the significant costs of hypoglycemic events —driven by ambulance calls, 
unplanned hospital admissions, and indirect costs associated with missed workdays or loss of 
work productivity—are well documented, LH costs have largely not been investigated, and 
remain essentially unknown.  (In England, the economic burden of hypoglycemia-related 
emergency calls totaled £13.6 million per year50, and average costs of hypoglycemia-related 
hospitalizations in Germany, Spain and the UK were €533, €691 and €537, respectively for 
patients with Type 2 diabetes and €441, €577 and €236, respectively for patients with Type 1 
diabetes.)51.  A direct and meaningful cost, directly linked with LH, is the cost associated with 
excess insulin consumption.  Individuals with LH inject on average 15 more units of insulin than 
those patients with without LH.  In Spain, this excess insulin consumption translated to a 
potential incremental insulin expense of €122 million per year to the Spanish Healthcare 
System48.   
LH and its associated burden is avoidable.  Proper site rotation has been demonstrated to 
have the greatest protective effect against LH formation48, and LH avoidance when injecting 
(among patients with LH) has shown to reduce A1c.  Avoiding needle reuse when injecting 
insulin is also believed to reduce the risk of LH, and is a part of the proper injection technique 




Although research in this area is still emerging, the global burden of diabetes continues to 
be daunting in both qualitative and quantitative ways.  In the case of LH, proper injection 
technique education is seemingly the solution. Healthcare workers’ awareness of the burden, 
along with reimbursement policies aimed at reducing PN reuse rates, may play a critical role in 
solving the problem.   
Compiling valid evidence of device-specific adherence is essential to developing 
interventions, however the bulk of research has focused on the burden of non-adherence to 
medication.  Non-adherence, with respect to medication, is defined as failure to take medicines 
as prescribed.  In the US and around the world, the burden of non-adherence is estimated to be in 
the billions.  Policy-based solutions, which include improved access, patient incentives and 
reporting, have been proposed to achieve adherence goals53,54. In the case of LH, studies have 
highlighted access problems—to an adequate supply of PNs—as a possible barrier for proper 
injection practices, specifically single-injection use as indicated55. Figure 1.6 illustrates how 
diabetes management, including adherence, injection technique and education, may play an 




Figure 1.6. Disease management modification to Bardenheier’s pathway to prediabetes56 
 
China is the most populous country in the world and has the most diabetic patients, with a 
corresponding healthcare burden that is only expected to rise.  With these challenges at the 
forefront of its legislative agenda, the country would stand to benefit from modifications to 
existing practices that could maximize current investment while delivering against China’s 
population health agenda.  Type 1 patients are insulin dependent at the time of diagnosis and 
Type 2 patients will grow to be insulin dependent at the late stages of the disease.  Insulin 
management is known to be costly and has recently been found to have delivery-related 
complications, such as LH, that impede optimal absorption and metabolism, impeding A1c 
control46. Correct injection practices are an important factor in achieving glycemic targets.  Thus, 
greater understanding of the effect of injection practices on patient outcomes could prove 
beneficial to patients and the broader system57,58.  To provide advice on the potential benefit of 
addressing LH in the Chinese population, or the necessary access and health education 




The only study to consider the burden of LH in China was a self-reported survey 
conducted in 2010.  This survey of 380 diabetes patients demonstrated an overall prevalence of 
35.26%, which was significantly correlated with the reuse of insulin pen needles.  That study 
provided insight to the poor state of injection practice and the potential magnitude of the problem 
in China, however limitations of the approach include self-report bias, lack of clinical 
confirmation of LH, and no data on insulin waste, cost, or reimbursement policy implications55. 
This research aims to address the gaps in the LH literature in China.  Efficacy of insulin 
therapy is dependent on proper insulin administration.  To understand whether further investment 
in injection-technique education may improve patient outcomes and reduce economic healthcare 
burden in China, evaluation of current injection practices, establishment of LH prevalence, and 
assessment of inter-province variability in reimbursement policy for insulin PN and patient 
outcomes must be investigated.   
Specific Aims 
The aims of this research are as follows: 
Aim 1:  Characterize the insulin injecting diabetic population and estimate the prevalence of LH 
in China  
• Describe clinical and economic characteristics of diabetic patients injecting insulin;  
• Establish a baseline for current insulin injection practices;  
• Determine the direct costs for diabetic patients injecting insulin;  
• Estimate the clinician verified prevalence of LH lesions;  
• Compare insulin consumption among those patients with and without LH.  
Aim 2: Explore the relationship between presence of pen needle reimbursement (PNR) policy, 




• Evaluate the relationship between presence of PN reimbursement and injection site 
rotation. 
• Evaluate the relationship between presence of PN reimbursement and LH prevalence and 
A1c. 
• Evaluate the relationship between presence of PN reimbursement and health resource 
utilization and medical expenditures. 
Primary data collected from a cross-sectional observational study conducted in 
partnership between Becton Dickinson and investigators from Southeast University Affiliated 
Zhongda Hospital, Chongqing Medical University No.1 Affiliated Hospital, Peking University 
People’s Hospital, and Zhengzhou University No.1 Affiliated Hospital was used to achieve these 
aims.  Laboratory, clinician and patient self-reported data was used to describe the Type 2, 
insulin injecting, diabetic patient population in China, and to examine the relationship between 





SECTION 2: LITERATURE REVIEW 
The prevalence of diabetes, as well as approaches to diabetes and related cost 
management, has been well documented around the world and continues to be a focus of the 
research community.  Although the occurrence of LH, a complication of insulin delivery, among 
diabetic patients has been recorded in the scientific literature for decades, only recently has there 
been a focus on understanding the potential repercussions of LH on the management of diabetic 
patients and health economies.    
To better understand the condition, its prevalence and impact, a PubMed abstract and title 
search was conducted on full-text Medline literature through June 2018 using the search terms 
LH and diabetes, resulting in 74 articles.  A secondary search was conducted using the combined 
search terms LH and prevalence, resulting in an additional 8 articles.  Article bibliographies were 
also reviewed for additional relevant literature.  References were limited to human studies 
reported in English.  Article titles and abstracts were screened for relevance and further 
examined for applicability to the research questions.   
Eligible studies addressed the topic of LH in conjunction with insulin administration via 
injection in the diabetic patient population.  Excluded studies were those addressing alternative 
routes of insulin administration (e.g., infusion or syringe), lipodystrophy in conjunction with 
HIV/AIDS, or as a dermatologic condition independent of diabetes management and independent 
case studies.  Studies exclusive to pediatric patients were also excluded, as the research dataset 
does not address this patient population.  Hypoglycemia and increased insulin consumption were 
noted as costable complications associated with LH, and were further explored in the literature.  




As noted earlier, the injection technique questionnaire (ITQ)is the most substantial source 
of literature available on the subject of insulin-injection practices and LH.  The survey 
demonstrates underdiagnosed increased insulin consumption, and higher A1c levels than insulin 
injectors without indication of LH.  LH patients in this study also had a higher prevalence of 
hypoglycemia and glucose variability.  The survey also demonstrated the significant prevalence 
of needle reuse among the population, and was able to further establish the self-reported 
causation to be both convenience and cost.  The practice of needle reuse was correlated with LH 
and glycemic variability47.  
LH prevalence data has shown to vary across studies and across regions.  In 2013, Blanco 
et al. demonstrated a 64.4% LH prevalence (76.3% Type 1, 56.1% Type 2) among insulin 
injecting patients in Spain.  The study also indicated a statistically significant relationship 
between LH and inadequate injection-site rotation, further suggesting that needle reuse may also 
increase the chance of LH development (not significant)48. In 2014, a 346 patient, 18 center, 
study in Italy showed an LH prevalence of 49.1%, which was further substantiated by a 2018 
estimate of 42.9%52,59. Additional studies in Germany, Ethiopia, Jordan and Turkey have 
demonstrated a total LH prevalence of 24%, 31%, 37.3% and 48.8%, respectively60-63. The ITQ 
found a global LH prevalence of 30.8% among patients who were examined by trained nurses47. 
See Table 2.1 for full review of LH prevalence64. 










McNally et al. 1988 281 United Kingdom 27.1 
 
  
Hauner et al. 1996 279 Germany 24 28.7 3.6 






Ibarra et al. 1998 150 Spain 52     
Partanen et al. 2000 100 Finland 
 
29   
Wallymahmed et al. 2004  74 United Kingdom   44   
Varder et al. 2007 215 Turkey 48.8 
 
  
Hajheyadari et al. 2011 220 Iran 14.5     
Cunningham et al. 2013 55 Ireland 51 
 
  
Blanco et al 2013 430 Spain 64.4 76.3 56.1 
Grassi et al. 2014 346 Italy 48.7 
 
  
Ji et al. 2014 380 China     35.3 
Ajlouni et al. 2015 1090 Jordan 
  
37.3 
Berard et al.  2015 503 Canada 24.6     
Frid et al. 2016 13289 Global 30.8     
Li et al. 2016 736 China 
  
73.4 
Patil et al. 2016 225 India 11.1     
Hernar et al. 2017 215 Norway 
 
63   
Pozzuoli et al. 2018 352 Italy 42.9     
 
 In total, the articles relating to LH prevalence in this review represented over 19,000 
patients (disproportionately ITQ) across 45 countries.  Definition of LH among all studies 
showed minimal variability.  Most referenced visibility, palpability and location of the lesion as 
defining factors of LH.  The most accurate method of LH detection was noted to be via 
ultrasound; however, the method can be costly and time consuming, and was only incorporated 
into one study48,64. Recent studies (with the exception of the Iran and India studies) reported 




patients with LH had higher occurrences of both unexplained hypoglycemia and glycemic 
variability than those without LH.  They also demonstrated higher economic burden due to 
greater insulin consumption.  The prevalence estimates, however, varied greatly across studies 
from 3.6-76.3% (Table 2.1).  Study quality, LH detection approach and investigator training may 
account for some of this variability. 
Most studies relied on a combination of manual detection and visual confirmation to 
determine the presence of LH. Few studies, however, offered a detailed description of 
investigator training in LH detection or method of observation and evaluation65,66.  As manual 
detection through palpation is the most common and practical approach, granularity in describing 
these methods will support the standardization necessary for comparability in future LH 
research.   
Moreover, not all studies described the qualifications of the researchers tasked with 
detecting and recording the presence of an LH lesion.  Variability in training and experience 
among these professionals both within and between studies may compromise the validity of the 
assessment and limit comparability across studies.  Study investigators should not only follow a 
uniform process for detection and confirmation to ensure accuracy in reporting, but should also 
control for years of investigator experience in their analysis to ensure that there is no inter-study 
variance among research staff.  Instances of patient self-report were few, but did demonstrate 
over-reporting when confirmed by a trained medical professional47.   
LH was commonly associated with needle reuse, injection frequency, and incorrect 
injection site rotation.  Incorrect injection site rotation was the most commonly cited risk factor 
followed by needle reuse; nonetheless, a standard definition for site rotation did not appear in the 




Lack of injection site rotation has been most commonly correlated with pain avoidance and 
patient education52,48,47,63.   
The heterogeneity of this research makes drawing conclusions across multiple studies a 
challenge.  Parameters such as needle gauge and needle length have also been positively 
correlated with LH or its predictive factors47.  However, studies of needle qualities do not control 
for such factors as duration of diabetes or duration of insulin exposure, which may confound the 
relationship between recent innovations in PN technology and LH prevalence.  These and other 
unexamined factors, such as health literacy, diet, culture and access to healthcare, could all 
contribute to the risk for LH.  Appropriate data is currently unavailable to examine these 
relationships64. 
 To address the issue of LH, the scientific community must have a keen understanding of 
LH-influencing factors and a dependable estimate of LH prevalence.  Much of the substantial 
work in this area has occurred in parallel over the past decade.  Future research will now be able 





SECTION 3: METHODS 
Conceptual Framework 
Among the most commonly used conceptual frameworks of health resource utilization is 
the Anderson Framework.  This framework, which has evolved over many iterations to explain 
drivers of patient behavior and choice, was originally developed to predict and explain the use of 
health services.  It was developed from the study of the family as a single unit of measurement, 
but progressed to the study of the individual as a unit of measurement to address the 
heterogeneity of the family variable.  The framework further evolved to consider systematic 
concepts of care and satisfaction as outcomes.  Today the framework integrates outcomes as an 
endpoint and includes a feedback loop to demonstrate the implications of outcomes on individual 
beliefs and future choices (Figure 3.1)67. 
The Andersen framework introduces mutability of predictive factors as a critical 
distinction in understanding resource utilization.  Mutability refers to how easily a factor can be 
changed.  A person’s demographic attributes are fixed and thus immutable, however, enabling 
factors, such as insurance status, can be altered and are thus mutable.  In the case of LH 
reimbursement policy, PN reuse and injection practices are mutable factors.  The framework also 
distinguishes potential access from realized access, highlighting that potential for accessing care 
is influenced by the presence of enabling resources.  Further, there is also a distinction between 
equitable and inequitable access, where equitable access is defined by immutable factors (e.g., 
demographic attributes) and inequitable access is an outcome influenced by circumstance (e.g., 




Figure 3.1. Andersen Framework of Healthcare Utilization67 
 
This framework presents health resource utilization as a sequence of access parameters, 
all of them in turn affected by environmental or systemic factors.  Individuals’ predisposing 
factors influence their propensity to use more or less healthcare.  Their enabling factors influence 
their ability to seek and acquire care.  Finally their level of need, or severity of illness, whether 
perceived or defined, drives the action.  The framework also allows the outcome to determine the 
individuals’ probability of engaging in future health resource utilization behavior.  This feedback 
loop in the framework suggests that a positive or negative outcome may influence patients’ 
predisposing belief about healthcare67.  The relationships highlighted in the Andersen framework 
are logical, however not actionable in the context of data available for this research.  The 
framework does, however, offer a way to analyze the directionality of the effect following a 




this study.  For example, if a patient’s diabetes is severe, then the Andersen framework predicts 
that that patient is more likely to use healthcare services, all else being equal.  This framework 
should allow for an intimate analysis of the relationship between predictive variables and the 
dependent outcomes of health resource utilization in this research 
Design 
 This is a cross-sectional study of observational data.  Further information on the design 
and methods is provided in the Data Source section below and in Ji et al. 2017 and 201868,69. 
Study Population 
Eligible study participants included individuals who received a clinical diagnosis of 
diabetes mellitus Type 1 or Type 2 and were receiving insulin therapy at the time of the study.  
Participants must have been administering insulin via pen and PN continuously for a period of at 
least 1 year.  Other inclusion criteria included being between the ages of 18 and 80 years, having 
a BMI ≥18.5 kg/m2, and being able to confirm that they were able to understand the 
investigator’s questions and complete the study questionnaire independently.  All participants 
provided informed consent prior to participation. 
Patients who do not self-inject or those taking insulin via pump or syringe were excluded 
from the study. Patients whose injection sites may have been compromised via a known cause 
such as surgery or other trauma, skin disorders (e.g., psoriasis, lupus, etc.) or skin 
imperfection/anomalies (e.g., discolorations, tattoos, or other abnormalities) were also excluded.  
Finally, individuals with diseases that would reduce the survival of red blood cells (e.g., sickle 
cell anemia, thalassemia, etc.) were also excluded, as these conditions may compromise 





The data for this study were collected through a multi-center observational study 
conducted at university hospital (Tier 3) clinics in Beijing, Zhengzhou, Chongqing, and Nanjing 
between December 2, 2013 and January 27, 2014; the former two sites were located in provinces 
that did not provide reimbursement for insulin PNs, whereas the latter two had provincial PNR 
policy in place.  Sequential patients attending the clinics were invited to participate in the study.   
Participants completed a questionnaire which included questions on demographic 
attributes and medical history, diabetes history, injection history, injection technique training and 
practices, frequency of hypoglycemia (self-reported), health resource utilization, employment, 
and income status.  Upon completion of the questionnaire, patients underwent a structured 
physical exam of height and weight, visual inspection and palpation of all injection sites, and 
HbA1c testing.  Study staff who performed physical examinations were trained to detect LH, 
first with models or mannequins, and then with patients known to have LH lesions. 
Data Limitations 
The data have several limitations, including those commonly associated with cross-
sectional study design.  Patients’ healthcare utilization (i.e., outpatient clinic visits and 
hospitalization) was solicited in the survey via self-report over a recall period of 6 months, 
potentially introducing recall bias.  Total healthcare costs associated with inpatient stays, 
outpatient visits, and insulin use were not directly solicited from participants, possibly masking 
true variability in costs between settings of care.  Unknown factors affecting quality of care and 
patient outcomes may have been missed.  Variability in scope of PN reimbursement policy 
including number of needles covered per insulin prescription, needle length or type, and 




relationships.  And lastly, the patient population only represents those from endocrinology clinics 
from a small sampling of tertiary hospitals in China, threatening external validity.  The study 
limitations section provides an in-depth analysis of the implications of these limitations.   
Measures 
 Lipohypertrophy is measured in 3 ways: (1) presence (i.e., prevalence) is a binary 
variable (0 = LH not present; 1 = LH present); (2) number indicates a count of LH nodes; and (3) 
length of longest LH node, in millimeters.   
 Several pen needle-related variables are measured.  Receipt of instruction in insulin 
injection is a binary variable, where 0 = no; 1 = yes.  Recency of instruction (either receipt or 
review) is a categorical variable with the following responses: within 6 months; between 6 and 
12 months prior to the survey date; 1 – 2 years prior; more than 2 years prior; 2 – 5 years prior; 5 
– 10 years prior; more than 10 years prior.  Rotation of insulin injection site is a binary variable, 
where 0 = no and 1 = yes.  Re-use of pen needles is a binary variable, where 0 = no and 1 = yes, 
and a categorical variable that measures degree (0 < times < 2; 2  times  6; 7  times  14; 15 
 times  28; times > 28).  Average number of times a pen needle is re-used is a continuous 
variable.  The value for participants who do not reuse pen needles is set to zero by the 
investigator.  Daily number of daily injections is a count variable.  Insulin type is measured by a 
dichotomous variable (0 = other; 1 = twice-daily premixed insulin).  Needle length is a 
categorical variable measured according to standard pen needle lengths (4 millimeters, 5 
millimeters, 6 millimeters, 8 millimeters).  Injection area size is a measure of the approximate 
dispersion region of injections on the abdomen.  Categorical responses, designed to be ordinal, 




 Diabetes-related health resources utilization is represented by a number of variables.  
Diabetes-related outpatient care is measured by number of visits (count variable) in the previous 
6 months, and outpatient costs, in RMB, calculated based on 374.1 RMB per outpatient visit.  
Diabetes-related hospital stay is a binary variable (0 = no; 1 = yes) that measures whether a 
participant was hospitalized in the previous 6 months for a condition/complication related to 
diabetes.  Inpatient costs are calculated for patients who were hospitalized in the previous 6 
months based on 6581 RMB per hospital stay.  The cost values for participants who did not 
report diabetes-related outpatient service use or a hospitalization is set to zero by the 
investigator.  Insulin costs are calculated based on responses to average daily number of units, 
with costs calculated based on 0.25 RMB per unit of insulin.  Out-of-pocket costs are self-
reported by participants.  Patients were dichotomized into lower- and higher-cost patients.  Total 
6-month diabetes-related cost comprises the sum of outpatient and inpatient services.  Patients 
with total 6-month costs at the 75th percentile or above were categorized as having “high” costs 
while those with total costs below the 75th percentile were classified as having “lower” costs.  
This cutoff was determined through an evaluation of the distribution of the data, which suggested 
that costs for these patients increased substantially upon reaching the 75th percentile. 
Participant age is a continuous variable, measured in years.  Gender represents biological 
sex, and is coded as 0 = female (referent); 1 = male.  Education level was collected as a 6-
category variable (primary school or below; junior school; high school; bachelor’s degree; 
master’s degree; other), but was dichotomized for analysis, so that 0 = bachelor’s degree or 
higher (referent); 1 = high school or less education.  Annual income was collected via a 7-
category response (no income; 0 < RMB  1000; 1000 < RMB  3000; 3000 < RMB  5000; 




categorical variable (because of low frequency responses in some categories) from which three 
binary dummy variables were constructed: no income (referent); 0 < RMB  3000; RMB > 3000.  
Medical insurance was similarly collected via a 6-category response, from which binary dummy 
variables were created: urban employee medical insurance (referent); urban resident medical 
insurance; new rural cooperation medical insurance; free medical insurance; other medical 
insurance; more than 1 type of medical insurance.  Pen Needle reimbursement is a binary 
variable, where 0 = has some level of PN reimbursement, and 1 = has no level of PN 
reimbursement.  BMI, calculated as kilograms/meters2, is treated both as a continuous variable 
and categorical variable, which dummied for analytic purposes: 18.5 < BMI < 24; 24  BMI 
<28; BMI  28.  
 Diabetes-related complications and other comorbid conditions are measured by binary 
variables indicating presence of the condition.  In all cases, 1 = presence of 
complication/condition, and 0 = absence.  Variables comprise: retinopathy, nephropathy, 
neuropathy, other diabetes-related complications, myocardial infarction (MI), cardiovascular 
disease (CVD), and hyperlipidemia. 
  Diabetes type is a binary variable, and is coded as 0 = Type 1 (referent) and 1 = Type 2.  
Duration of diabetes and duration of insulin therapy are both continuous variables, measured in 
years.  Daily insulin dose, measured in International Units (IU), and IU per kilogram, are both 
continuous variables.  Glycated hemoglobin (HbA1c) is a continuous variable, measured in 
percent (National Glycohemoglobin Standardization Programme) and mmol/mol (International 
Federation of Clinical Chemistry).  For analytic purposes it was always dichotomized at its 




in the previous 6 months was a self-reported categorical variable that was dummied, according to 
its original responses, as follows: none (referent); 1 - 2 events; 3 or more events.   
Analytic Approach 
Aim 1:  Characterize the insulin injecting diabetic population and estimate the prevalence 
of LH in China 
Univariate methods were used to characterize the insulin injecting diabetic population in 
China for the full sample and stratified by LH status.  Means were generated for continuous 
variables, frequencies were run for categorical variables, and applied bivariate methods (i.e., t-
test, Wilcoxon Rank Sum test or ANOVA for continuous variables; chi-square test for 
categorical variables) were used to compare attributes across LH strata.  Pearson’s correlations 
were calculated between total daily dose of insulin and both BMI and weight.   
Logistic regression was used to analyze the cross-sectional association between LH and 
explanatory variables, including duration of insulin therapy, number of daily injections, gender, 
BMI, weight-adjusted insulin dose, HbA1c, site rotation, PN length, PN reimbursement, and 
frequency of PN reuse.  Point estimates of odds ratios and 95% Confidence Intervals (CI) were 
generated for LH predictors.  A stepwise approach, with subsequent point estimates and ORs, 
was fitted to generate multivariable models. 
IMS MIDAS data combined with public and private resources were used to derive unit 
costs for insulin and healthcare resource utilization in China Unit costs for insulin were estimated 
to be 0.25 RMB70. The 4th China National Health Services Survey conducted by the China Ministry 
of Health was used to obtain unit costs for outpatient and hospital services71. Consumer price index 
for medical goods in China was used to inflate figures to 2015 RMB (374.1 RMB, outpatient and 




spending were converted to 6-month costs by multiplying the daily insulin costs by a factor of 182 
and four-week patient OOP spending by a factor of 6.5.  Total 6-month costs were calculated for 
patients by summing the total costs for outpatient visits, hospitalizations, insulin costs and patient 
OOP spending for PNs.  All costs were inflated to 2015 RMB69.   
Insulin consumption costs were further evaluated by LH status.  Differences in insulin 
consumption were used to assess economic burden of excess inulin required to achieve glycemic 
control.  Cost of excess insulin consumed was calculated by multiplying average excess units 
used by a standard insulin unit price of 0.25 RMB70. This cost of the observed difference in 
insulin used was then extrapolated to the insulin-injecting population in China48.  
Aim 2: Explore the relationship between PNR policy, injection practices, clinical outcomes 
and direct costs among insulin injecting diabetics in China  
To explore the relationship between PNR policy, injection practices, clinical outcomes 
and direct costs among insulin injecting diabetics in China, descriptive statistics (i.e., mean, 
median, SD or 95% confidence interval) were compared for patients with and without insurance 
coverage for PN using chi-square as well as Student’s t-test or Wilcoxon Rank Sum test.   
Because the same unit costs are applied for each patient, it is likely that evaluation of the 
total costs in a regression model will result in artificially low variances and increased Type II 
error.  To reduce the potential for this bias, the effect of PN reimbursement on total costs was 
evaluated using a logistic regression model that dichotomized patients into lower- and higher-
cost patients.  Income, education, age, gender, insurance, income, type and duration of diabetes, 
duration of insulin use, frequency of hypoglycemia in the prior 6 months, BMI, and presence of 
cardiovascular disease, hyperlipidemia, retinopathy, nephropathy, neuropathy, presence of other 








SECTION 4: RESULTS 
Clinical and Demographic Characteristics of the Sample 
Of 403 patients who provided informed consent, 401 completed the study procedures and 
results are described for them.  Clinical and demographic information is provided in Table 4.1.  
Data are provided for the full sample and stratified by LH status.  Patients were nearly 60 years 
old and 50% male.  Patients had diabetes for nearly 12 years, > 93% Type 2, and had been taking 
insulin for a mean of 5.8 years (range 1-29.3 years).  400 of the 401 patients who completed 
study procedures also provided reimbursement information.  More than 98% of these patients 
had some medical insurance; 142 (35.5%) had medical insurance that covered a portion of PNs 
costs.  Mean HbA1c was 8.0% (SD 1.7% [64 mmol/mol]) in the study population. Nearly 60% of 
participants had an occurrence of hypoglycemia in the 6 months prior to the survey.  Average 
BMI was 25.4 kg/m2, and ranged from 18.8 to 41.4 kg/m2, with ~ 31% between 18.5 and 24 
kg/m2, 51% between 24 and 28 kg/m2, and 18% > 28 kg/m2.  The largest proportion (49.3%) of 
the 213 subjects with LH had BMI between 24 and <28 kg/m2.  Viewed differently, 56 of the 
123 (45.5%) subjects with BMI < 24 kg/m2 had LH, compared to 105/205 (51.2%) with BMI 
between 24 and <28 kg/m2, and 52/73 (71.2%) subjects with BMI ≥ 28 kg/m2.   
Duration of diabetes did not differ significantly between those with and without LH; 
duration of insulin injection was numerically longer, though not statistically so, in those with LH 
(p=0.069).  LH was present in 19 of 26 (73.1%) subjects with Type 1 diabetes and 193 of 374 
subjects (51.6%) with Type 2 diabetes (p=0.034).  Compared to patients without LH, those with 
LH had higher BMI (26.0 vs 24.8 kg/m2), took more insulin daily (38.1 vs 27.1 IU), more 




7.7% [66 vs 61 mmol/mol]) (all p ≤ 0.01).  There was a significant positive relationship between 
BMI and LH prevalence, p =0.002.   









Age, years 59.6 (11.5) 59.8 (11.2) 59.3 (11.9) 0.655 
Gender (male) 200 (49.9%) 111 (52.1%) 89 (47.3%) 0.340 
Diabetes duration, years 11.8 (7.3) 12.4 (7.7) 11.3 (6.8) 0.145 
Type 2 diabetes 374 (93.3%) 193 (90.6%) 181 (96.3%) 0.034 
Duration insulin therapy 
- years 
5.8 (4.5) 6.2 (5.0) 5.4 (4.0) 0.069 
Daily insulin dose - IU 








































Data are N (and percentage).  Mean (SD), or median as noted.  P-value relates to t-test or chi-square test of 
difference in attribute between participants with and without LH.   
*Hypoglycemia is self-reported within the past 6 months. 
  Table 4.2 presents diabetes-related healthcare utilization and expenditure data.  Nearly 
two-thirds of the study population reported at least one diabetes-related outpatient (OP) visit 
(62.7%) and 14.4% of the sample had at least one hospital stay in the previous 6 months.  The 
average number of diabetes-related OP visits and hospital stays per patient was 2.55 (SD 2.55) 




patients reporting a range from 6 - 118 units per day. The average expenditure on OP and 
inpatient services over a period of 6 months were 1,058 (1057.7) and 1,291 (SD 3,762.1) RMB, 
respectively, however diabetes-related hospital costs were reported as high as 43,760 RMB.  
Average daily insulin costs for this study population were 7.08 RMB.  Self-reported OOP costs, 
over a period of 6 months, were reported between 0 and 3,330 RMB with an average of 289 
RMB (284.8).  
Table 4.2. Total Diabetes Related Healthcare Resource Utilization  
 
All 
Any DM-related OP Visits (% of total) 252 (62.7) 
Any DM-related Hospital Stay (% of total) 58 (14.4) 
Number of DM-related OP Visits  
Mean (SD) 




1 (0, 5) 
0, 10 
Number of DM-related Hospital Stays 
Mean (SD) 
Median (Q1, Q3) 
Min, Max  
 
0.177 (0.516) 
0 (0, 0) 
0, 6 
Daily Insulin Dose 
Mean (SD) 
Median (Q1, Q3) 
Min, Max  
 
33.95 (18.41) 
30 (20, 42) 
6, 118 
BMI-Normalized Daily Insulin Dose (n=401) 
Mean (SD) 




1.19 (0.77, 1.69) 
0.24, 4.92 
DM-Related OP Costs in RMB (n=400) 
Mean (SD) 




415 (0, 2073) 
0, 4146 
DM-Related Hospital Costs in RMB (n=401) 
Mean (SD) 









Daily Insulin Cost in RMB (n=402) 
Mean (SD) 




6.45 (4.3, 9.0) 
1.29, 25.37 
BMI-Normalized Insulin Cost in RMB (n=402) 
Mean (SD) 
Median (Q1, Q3) 
Min, Max  
 
0.28 (0.15) 
0.26 (0.16, 0.36) 
0.05, 1.06 
Reported 6- month OOP Costs in RMB (n=375) 
Mean (SD) 
Median (Q1, Q3) 
Min, Max  
 
289 (284.8) 
220 (114, 381) 
0, 3300 
Data are N (percentage), Mean (SD), or median as noted.   
*OOP is self-reported for 4 weeks and extrapolated to 6 months 
Lipohypertrophy prevalence, characteristics, and extrapolated cost 
In Table 4.3, we present LH prevalence and characteristics. Overall LH prevalence was 
53.1% (95% CI 48.2, 58.0), most commonly found in the abdomen (52.4%), which was used as 
an injection site by 391 or 97.5% of subjects, followed by the thigh (LH in 15.5%) and arm 
(9.4%); LH was not present in the buttocks, however only 29 (7.2%) subjects used this area for 
injections.  In participants with LH, 2.3 (SD 2.2) lesions were found on average, and ranged from 
1 to 20.  The average length of the longest dimension of a lesion was 16.1 mm, with a maximum 
80 mm.    
Table 4.3. Lipohypertrophy Prevalence, Location, and Lesion Length  
 
Total All 
Overall prevalence: % of total N (95% CI) 401 53.1 (48.2, 58.0) 
Physical Location of LH Lesion among LH patients 
Abdomen, number (%) 
Thigh, number (%)  






























Figure 4.1 presents the relationship between BMI and total daily dose (TDD) of insulin in 
all subjects.  Pearson’s r values for correlation were not significant: 0.277 for TDD and BMI; and 
0.247 for TDD and weight (kg).  Correlations were also assessed separately between BMI and 
TDD of insulin in subjects with and without LH, with R values = 0.284 and 0.159, respectively 
(see Figures 4.2 and 4.3). 
Figure 4.1. Scatter plot for BMI vs total daily dose (TDD) of insulin in all study subjects 





Figure 4.2. Scatter plot for Total daily insulin dose with BMI for subjects with LH  





Figure 4.3. Scatter plot for Total daily insulin dose with BMI for subjects without LH 
R = 0.159, R2 = 0.025 
 
A 2014 China IMS report estimated the number of insulin injecting patients to total 9 
million73.  This estimate multiplied by the study established prevalence (53.1%) and an average 
excess daily consumption of 11IU of insulin in LH patients totals 52,596,000 excess units of 
insulin consumed by insulin injecting patients with LH in China annually.  Total daily costs for 
insulin of 9.5 (LH) vs 6.8 (no-LH) were calculated using the IMS reported average price of 
insulin of 0.25RMB per unit70.  The total cost of excess insulin consumption totaled RMB 
4,709,704,500.  However, this estimate assumes perfect adherence.  IMS data indicated that 
insulin injection adherence in China is 42% (or 154 injection days)73.  When adjusting for 
adherence, the estimated cost of excess insulin consumption in insulin injecting diabetes patients 




Insulin injection practices 
Table 4.4 provides information related to insulin-injection technique.  Roughly ninety 
percent of participants had received some (any) injection training (~15% within the past 12 
months), and nearly 97% claimed they rotated their injection sites; correct site rotation was 
documented in more subjects without LH (93%) than in those with LH (68%), p< 0.001.  Needle 
reuse was common and reported by 95% of patients.  Reuse did not differ between those with 
and without LH; however, median frequency of reuse was significantly greater in those with LH, 
13 times vs 7.5 times (p=0.003), with one subject (with LH) who took insulin twice daily 
reporting use of a single needle for 6 months, or 360 times.  Patients with LH took >20% more 
injections daily than patients without LH (p<0.001).  Patients in the study most commonly used 
5mm needles (nearly 60%), followed by 6mm, 8mm, and 9.6% who used 4mm.  There were no 
differences between needle length in those with or without LH.  In the most commonly used 
injection site (abdomen), patients reported using a variety of injection size areas – most 
commonly that of a playing card (nearly 43%).  There were marginal differences, although not 
statistically significant, in the distribution of the size of injecting areas between those with and 
without LH, p = 0.061. 









Received training – any 









Site rotation correct 318 (79.3%) 144 (67.6%) 174 (92.3%) <0.001 
Needle reuse - Yes 381 (95.0%) 206 (96.7%) 175 (93.1%) 0.096 
Needle reuse – frequency 
(median, Q1-Q3) 


























Number of injections daily 2.1 (1.0) 2.3 (1.0) 1.9 (0.9) <0.001 
Twice-daily premixed insulin 215 (53.6%) 118 (55.4%) 97 (51.6%) 0.446 










































Needle reimbursement - Yes 142 (35.5%) 59 (27.8%) 83 (44.2%) <0.001 
Data are N (and percentage).  Mean (SD), or median as noted 
 
Predictors of lipohypertrophy prevalence 
Based on stepwise logistic regression, five factors demonstrated a significant, 
independent correlation with LH prevalence (Table 4.5).  Increasing BMI, needle reuse 
frequency, and lack of PN reimbursement had ORs for LH prevalence between 1.1 and 1.9 (all p 
≤ 0.03).  Total weight-adjusted insulin dose and lack of correct site rotation had ORs of nearly 
7.0 and 8.4, respectively, with p-values < 0.001.  Nevertheless, confidence limits on these point 
estimates are rather wide, suggesting imprecision in the estimates. 
Table 4.5. Stepwise Logistic regression results for prevalence of LH 
Parameter β  OR 95% CI of OR p-value 
Intercept  -4.249   <0.0001 




Frequency of needle reuse 
>7 Vs ≤ 7 
0.5709 1.77 1.07, 2.92 0.0253 
Lack of PN Reimbursement 0.6163 1.85 1.11, 3.10 0.019 
Insulin Dose per Weight 1.9401 6.96 2.32, 20.8 <0.001 
Correct Site rotation (No vs Yes) 2.1266 8.39 4.15, 17.0 <0.0001 
For stepwise logistic regression, included variables are: Age (years), gender, BMI (kg/m2), pen needle 
reimbursement status (Yes, No), Duration of insulin therapy (years), Instructions on injection (Yes, No), Site 
rotation (Yes, No), number of daily injections, Total daily insulin dose per weight (U/kg), HbA1c (%), needle length 
(≥6mm vs 4mm and 5mm), and PN reuse (Frequency ≤7, Frequency > 7). P value < 0.05 significant. 
 
Relationship between PN reimbursement and study variables 
The results that follow (Tables 4.6 – 4.9) describe the association between PN 
reimbursement and several domains of variables: demographic factors, clinical characteristics, 
PN utilization behavior, and diabetes- and insulin-related healthcare utilization and expenditures.   
Table 4.6 includes comparisons of demographic characteristics by PN reimbursement 
status.  Patients with PN reimbursement were older (62.4 vs 58.0 yrs., p<0.001) but there were 
no significant differences in gender or education.  There was, however, a significant difference in 
distribution of medical insurance types between participants with and without PN 
reimbursement.  The majority of patients with PN reimbursement had access through Urban 
Employee Medical Insurance (87.2%).  The most common insurance type among those without 
access to PN was also Urban Employee Medical Insurance (41.1%), followed by Urban Resident 
Medical Insurance (26.1%) and New Rural Cooperation Medical Insurance (19.0%).  Individuals 
with and without access to PN reimbursement also had variation in their income distributions.  
Patients without PN reimbursement likely had lower income, with 11.6% of patients reporting no 




Table 4.6.; Demographic Characteristics, by PN Reimbursement Status 
Characteristics 








Patient age (years) 
 Mean (SD) 
 Median (Q1, Q3) 
 
62.4 (9.60) 
63 (57, 70) 
 
58.0 (12.2) 




 Male (%) 









 Primary school level or below (%) 
 Junior school level (%) 
 High school level (%) 
 Bachelor’s degree (%) 
 Master’s degree or above (%) 
















Type of medical insurance†‡ 
Urban employee medical insurance 
(%) 
Urban resident medical insurance (%) 
New rural cooperation medical 
insurance (%) 
Commercial insurance (%) 
Free medical service (%) 
Other (%) 























 No income (%) 
 Below 1000 RMB (%) 
 1001-3000 RMB (%) 
 3001-5000 RMB (%) 
 5001-10000 RMB (%) 
 10001-25000 RMB (%) 


















Q1 = lower 25th percentile; Q3 = upper 25th percentile; SD: standard deviation 
*P-values were obtained using the χ2 test, with the exception of education level where the Fisher Exact test was 
used; p-values < 0.05 were considered to be statistically significant 
†Percentages represent column percentages 





Table 4.7 compares the study population’s clinical characteristics across PN 
reimbursement status.  Type 2 diabetes was more common among participants with PN 
reimbursement (97.2% vs. 91.4%), whereas Type 1 diabetes was more common among those 
without reimbursement (8.6% vs. 2.8%) (p =.026).  HbA1c, BMI, frequency of hypoglycemic 
events and duration of insulin treatment did not differ between participants with and without PN 
reimbursement (p>0.05).  However LH was more prevalent among those who did not have 
coverage for PNs (59.3% vs. 41.6%, p = 0.0007); furthermore, the number of LH nodes was also 
higher in non-reimbursed group (2 vs. 1 per patient, p < 0.0001).  Compared to those without 
insurance coverage for PNs, a higher percentage of patients with insurance coverage for PNs had 
cardiovascular disease (61.3% vs. 39.9%, p < 0.0001) and hyperlipidemia (54.2% vs. 18.6%, p < 
0.0001) (see Table 4.5). 
Table 4.7: Clinical Characteristics, by PN Reimbursement Status 
Variable 
Patients with PN 
Reimbursement 
(N=142) 




Type of diabetes† 
 Type 1 (%) 









Duration of time with diabetes 
(years) 
 Mean (SD) 












HbA1c   
 Mean (SD) 
 Median (Q1, Q3) 
 
8.0 (1.53) 
7.6 (6.8, 8.9) 
 
8.0 (1.76) 




 HbA1c < 7% (%) 










 Mean (SD) 
 Median (Q1, Q3) 
 
25.1 (3.09) 
24.8 (22.7, 27.1) 
 
25.6 (3.20) 






Frequency of hypoglycemia in 
previous six months† 
 0 (%) 
 1-2 (%) 













Duration of insulin therapy (years)  
 Mean (SD) 
 Median (Q1, Q3) 
 
5.9 (5.01) 
5 (2, 8) 
 
5.4 (4.27) 
4 (2, 8) 
 
0.444 
Presence of CVD† (% Yes) 87 (61.3) 103 (39.9) < 0.001 
Presence of hyperlipidemia† (% Yes) 77 (54.2) 48 (18.6) < 0.001 
Presence of lipohypertrophy† (% 
Yes) 
59 (41.6) 153 (59.3) <0.001 
Number of lipohypertrophy nodes 
     Mean (SD) 
     Median (Q1, Q3) 
 
1.5 (0.68) 
1 (1, 2) 
 
2.7 (2.46) 
2 (1, 3) 
 
< 0.001 
Longest diameter of lipohypertrophy 
nodes 
     Mean (SD) 












*Differences in continuous variables were tested using Wilcoxon Rank Sum tests for non-normally distributed 
variables and the Student t-test for normally distributed variables; differences in categorical variables were tested 
using χ2 tests; p-values < 0.05 were considered significant 
†Percentages represent column percentages 
CVD: cardiovascular disease; HbA1c = hemoglobin A1c; Q1 = lower 25th percentile; Q3 = upper 25th percentile; 
SD: standard deviation 
 
PN training and injection practices are compared by reimbursement status in Table 4.8.  
The vast majority of patients reported receiving instructions on insulin injections and rotating 
injection sites regardless of reimbursement status.  Patients without PN reimbursement did, 
however, report reusing PN significantly more (97.3% vs. 90.9%; p = .005) and reusing them 






Table 4.8. PN Reuse and Related Factors, by PN Reimbursement Status 
Parameter 
Patients with PN 
Reimbursement 
(N=142) 




Subject ever received instruction on 
insulin injections† (% Yes) 
 Yes (%) 












Most recent receipt or review of 
injection instruction† 
 Within the past 6 months (%) 
 Within the past 6-12 months 
 More than 1 year ago 
 More than 2 years ago 
 More than 5 years ago 




















Subject rotates inulin injection site† 
(% Yes) 
 Yes (%) 












Subject re-uses pen needles † (%Yes) 129 (90.9) 251 (97.3) 0.005 
Number of times a single PN is reused 
by the subject  
Mean (SD) 












*Differences in continuous variables were tested using Wilcoxon Rank Sum tests for non-normally distributed 
variables and the Student t-test for normally distributed variables; differences in categorical variables were tested 
using χ2 tests; p-values < 0.05 were considered significant 
†Percentages represent column percentages 
Q1 = lower 25th percentile; Q3 = upper 25th percentile; SD: standard deviation 
Table 4.9 presents the results of comparisons of healthcare resource utilization and 
related expenditures by PN coverage status, which suggest minor differences.  Number of 
diabetes-related outpatient visits were comparable between the two groups (1 vs. 2, p = 0.223).  
Even so, a larger percentage of those without PN coverage had at least 1 hospital stay (17.4% vs. 
9.1%, p = 0.023 and greater daily total unstandardized daily insulin use (35.0 vs. 29.2 units, p = 
0.026).  After standardization (dividing daily insulin doses by the patient’s body weight in 




reimbursement (0.50 vs. 0.45 units/kg body weight; p = 0.041). Comparisons of 6-month 
healthcare expenditures suggest that patients without PN reimbursement experienced greater 
hospital expenditures (1589 RMB vs. 773 RMB, p = 0.038), insulin costs (1591 RMB vs. 1328 
RMB, p =0.003), and self-reported OOP costs (2217 RMB vs. 1226 RMB, p < 0.001).  The total 
6-month standardized expenditures, after excluding patients with missing cost data (1 
observation had missing cost data for outpatient costs), were 6433 RMB for patients without PN 
reimbursement and 4432 RMB for those who had PN reimbursement (difference significant at p 
< 0.001).  Diabetes related outpatient costs were not different between groups (p = 0.55). 
Table 4.9. Estimated Diabetes and Insulin-related Healthcare Utilization and Expenditures, 
by PN Reimbursement Status 
 
Patients with PN 
Reimbursement 
(N=142) 




Resource Utilization in Prior 6 Months 
   
Number of Diabetes-related   Outpatient 
Visits During Prior Six Months† 
 Mean (SD) 




1 (0, 6) 
 
 
2.50 (2.42)  




Any Diabetes-related Hospital Stay 
During Prior Six Months (% yes)† 
13 (9.2) 45 (17.4) 0.023 
Daily Insulin Dose (in Units) 
 Mean (SD) 
 Median (Q1, Q3) 
 
29.18 (13.72) 
29.5 (18.0, 38.0) 
 
34.97 (20.28) 
30.0 (20.0, 44.0) 
 
0.026 
Daily Insulin Dose per kg of Body 
Weight  
 Mean (SD) 












Costs in Previous Six Months (reported 
in 2015 RMB) 
   
Diabetes-Related Outpatient Costs^  
 Mean (SD) 
 Median (Q1, Q3) 
 
1105 (1160.5) 
416 (0, 2497) 
 
1040 (1006.9) 







Diabetes-Related Hospital Costs^ 
 Mean (SD) 
 Median (Q1, Q3) 
 
773 (2717.0) 
0 (0, 0) 
 
1589 (4231.8) 




 Mean (SD) 
 Median (Q1, Q3) 
 
1328 (624.4) 
1342 (819, 1729) 
 
1591 (922.9) 
1365 (910, 2002) 
 
0.003 
Reported OOP Costs 
 Mean (SD) 
 Median (Q1, Q3) 
 
1226 (933.3) 
995.5 (679, 1580) 
 
2217 (2079.1) 
1761.9 (891, 2937) 
 
< 0.001 
Total Diabetes-Related Costs  
 Mean (SD) 
 Median (Q1, Q3) 
 
4432 (3376.3) 
3850 (2135, 5388) 
 
6433 (5147.2) 
5075 (3441, 7576) 
 
< 0.001 
†Values represent outpatient visits and hospital stays during the past 6 months 
*Differences in continuous variables were tested using Wilcoxon Rank Sum tests and categorical variables (any 
diabetes-related hospital stay) using χ2 tests; p-values < 0.05 were considered significant 
BMI = body mass index; DM = diabetes mellitus; kg: kilogram; OOP = out-of-pocket; PN = pen needle; Q1 = lower 
25th percentile; Q3 = upper 25th percentile; SD = standard deviation; 
^Unit costs: 1) insulin costs 0.25 RMB per unit; 2) outpatient/ER visits are 374.1 RMB per visit; 3) and hospital 
stays are 6,581 RMB per stay  
 
Predictors of high healthcare expenditures 
The results of a multivariable logistic analyses of factors related to having total direct 
healthcare expenditures above the 75th percentile are presented in Table 4.10.  After adjusting for 
demographic and clinical characteristics, patients without PN reimbursement had 4.56 times the 
odds of having high costs as those with PN reimbursement (OR = 4.56, 95% CI = [2.14, 9.75], p 
= <0.001).  Other factors in the model associated with having high costs included presence of 
retinopathy (OR = 2.08, 95% CI = [1.13, 3.85], p = 0.019), and presence of neuropathy (OR = 







Table 4.10. Factors Associated with Total Direct Healthcare Expenditures in Previous Six 
Months in the Top 25th Percentile†  
Parameter OR 95% CI p-value* 













High School and Below 









Type of Insurance 
Urban Employee Medical Insurance* 
Urban Resident Medical Insurance 
New Rural Cooperation Medical Insurance 
Free medical service 
Other 























 No income (ref) 
 3000 RMB or below 













Subject has some level of PN Reimbursement 
 Yes (ref) 










Type of Diabetes 
 Type 1 (%)  (ref) 










Duration of diabetes  0.96 0.91, 1.01 0.131 
Duration of insulin 1.03 0.95, 1.12 0.417 
Hypoglycemia frequency in previous six months 
 None (ref) 
 1 to 2 













BMI 1.09 1.00, 1.20 0.055 
Presence of CVD 1.84 0.98, 3.48 0.060 




Retinopathy 2.08 1.13, 3.85 0.019 
Nephropathy 0.90 0.41, 2.00 0.798 
Neuropathy 2.92 1.56, 5.49 <0.001 
Other complication 1.03 0.35, 3.05 0.958 
*p-values < 0.05 were considered significant 
†Total costs under the 75th percentile of costs were considered to be low costs; costs at and above the 75th percentile 
were considered to be high costs; the cut-off point was based upon the distribution of costs in the data. 






SECTION 5: DISCUSSION AND CONCLUSION 
 
Prior to this investigation, little was known about the problem of LH in China, in 
particular its relation to PN reimbursement.  This research is the first to assess the prevalence of 
LH in China with clinical confirmation and accompanying insulin and injection technique data.  
The additional innovation in this research is the assessment of access to insulin delivery, as 
opposed to an evaluation of insulin effect and associated outcomes.  This study established that 
the prevalence of LH in China (53.1%) is significant, that injection practices associated with LH 
in the literature (such as site rotation) are also risk factors in the Chinese patient population, the 
presence of LH is correlated with clinically meaningful differences in HbA1c, and patients who 
lack PN reimbursement exhibit higher frequency of PN reuse as well as higher insulin and total 
health care costs than those with reimbursement.  
The population in this study was representative of the general diabetic population in 
China as reported by published surveys34,37.  However, it is important to note that 87.2% of 
diabetics in this study were covered by the insurance scheme UEMI, which is not representative 
of the general Chinese population.  This parameter may have been influenced by site selection, 
as tertiary settings are often more costly points of care and may draw patients with 
disproportional means.  For this reason, extrapolation of findings beyond tertiary care settings 
should be done with caution.   
The prevalence and risk factors findings of this study are similar to those generated by 
examinations of LH elsewhere.  Studies conducted in Spain, Turkey, Italy and Norway, all 
utilizing trained nurses, also demonstrated the presence of LH in approximately half the study 
population (64.4%, 48.8%, 48.7%, 47.4% respectively)48,52,64.  However, LH prevalence figures 




diagnosis64,55.  This also supports the ITQ guidance, which recommends annual injection site 
inspection, but also further highlights an opportunity for patient education on injection site 
inspection and LH detection.   
The Spanish study of LH prevalence was the first to investigate the impact of LH lesions 
on differential insulin consumption.  That research identified a consumption difference of 21 IU 
(48%) more insulin per day in those with LH than those without48.  This study has identified a 
significant (11 IU) difference in insulin utilization between patients with and without LH (38.1 
vs 27.1 IU, 40%, p<.001).  The difference remained substantial after adjusting for BMI, which 
was not controlled in the previous research (.54 vs .41 IU/kg, 31.7%, p<.001).  Since BMI was 
significantly higher for patients with LH in this study, a correlation with TDD was explored 
(Figure 4.1 – 4.3).  The low R2 values suggest that factors other than BMI affect insulin 
consumption.  
A crossover euglycemic clamp study of Type 1 diabetes patients who received constant 
dose insulin injections into LH and normal tissue found that LH tissue significantly stunts insulin 
absorption.  Post prandial blood glucose levels were also higher when insulin was injected into 
the LH tissue.  Although the study was not powered for hypoglycemia, there was also a 
numerical difference in the prevalence between LH and normal tissue injections46. This has an 
important implication for the insulin-injecting diabetic population in China, namely that 
suboptimal insulin management is likely contributing to the observed rise in cost. 
Diabetes is noted to be one of China’s largest healthcare cost drivers14. Although little 
research has studied treatment-stratified diabetes patients in China, estimates of market sales of 
insulin in the country reached 9 billion dollars73. This research suggests that the adherence-




fifth of China’s total insulin expenditure.  The Blanco et al. study examined a similar relationship 
in Spain, estimating local opportunity cost of 122 million Euros in excess insulin consumption 
due to LH.  That study did not, however, capture HbA1c values.  No conclusion could therefore 
be drawn regarding the impact of excess insulin use and patient outcomes48. This particular 
limitation was addressed in the current research, which found that in addition to having 
significantly higher insulin utilization, patients with LH in China had higher HbA1c levels 
(0.5%).  This further supports the hypothesis that injecting into LH lesions, which are believed to 
disrupt insulin absorption, leads to poor glycemic control at a substantial cost to the healthcare 
system.  Efforts to increase insulin therapy adherence need to be accompanied by proper delivery 
education to avoid additional economic burden due to excess insulin consumption.       
Pen needles are an important component of insulin delivery among insulin-requiring 
patients with diabetes.  Despite this, only 35.6 percent of patients in this study reported having 
had any kind of reimbursement for their PNs (exact coverage could not be verified).  This has 
important implications around patients’ overall care, outcomes and costs.  Patients who lack PN 
reimbursement may have significant unmet needs (compared to those who have their PNs 
reimbursed).  These patients had a higher prevalence of LH and increased hospitalizations, 
insulin use, and overall costs.  Although these associations do not indicate causality, they 
nonetheless indicate that these patients represent a population in which improvements in 
treatment are required to improve their outcomes and decrease overall costs.  
Patients without PN reimbursement had greater costs than those with PN reimbursement, 
even after controlling for various clinical and demographic characteristics.  A large portion of 
these increased costs is likely attributable to hospitalizations, as significant differences in 




than other costs (i.e., insulin costs).  Although not directly attributable to PN reimbursement in 
this study, increased diabetes-related hospitalization and costs nonetheless indicate that these 
patients experience greater complications that require more intensive medical care. 
Patients without PN reimbursement also had increased insulin costs, as a function of 
greater insulin utilization.  The difference in daily average insulin costs (1.45 RMB per day) 
amounts to approximately 529 RMB per year.  Despite their greater utilization of insulin, 
patients without PN reimbursement had similar average HbA1c levels as those with PN 
reimbursement, implying that these patients required more insulin to control their blood glucose.  
The clinical significance of this association is unclear.  One reason why this was observed may 
be due to an increased observed prevalence of LH among these patients.  
Despite most patients’ in the study reporting they had received injection instruction at 
some point in their lives, only 16.8% received instruction in the year prior.  Proper site rotation, 
as defined by this study to be both site rotation and moving the injection point at least 1 
centimeter away from the prior injection point, was poor overall.  However, upon sub-analysis, it 
was observed that while patients with PN reimbursement did not move the injection point at least 
1 centimeter away from the prior injection point significantly more often, they did rotate sites 
significantly more often, which was associated with a lower prevalence of LH.  The difference in 
site rotation practices among the reimbursed population may allude to a variance in the type of 
instruction received by those reimbursed for PNs, which was not assessed in this study. Patients 
who did rotate generally may have had the intention of proper site rotation, but lack of education 
on injection technique, or retention, could have undermined their efforts.  This finding 
emphasizes the need for more frequent education on proper injection technique.  Policies 




with training on techniques to improved health literacy among patients, may begin to address this 
issue.  
In this study, needle reuse was also prevalent among all study participations (95%) and 
no correlation with LH was initially detected.  Upon further investigation, it was determined that 
reuse frequency was associated with LH prevalence (p=0.003) suggesting that reuse is still a 
meaningful target for improvement.  The Spanish LH study found that reuse greater than 5 times 
is significantly associated with the presence of LH in insulin-injection patients48. Another cross-
sectional study by Ji et al., conducted in 2010 among 380 diabetes patients across 20 centers in 
mainland China, also found a significant positive relationship between the frequency of single 
needle reuse and LH55. In the Ji study, the mean number of uses per needle was 9.2, with 
approximately 26.8% of patients using the PN 10 or more times.  Among patients who reused 
their needles, the most frequent reasons for reusing were for convenience and cost saving.  In this 
study, more patients without PN reimbursement reused their PNs, and did so more frequently 
than those that had PN reimbursement.  PNs are intended for single-use only, yet many 
patients—especially those without PN reimbursement—reused their PNs.  It is possible that both 
repeated utilization of a single injection site, coupled with blunted needle tips (resultant of 
reuse), may be meaningful contributors of LH in insulin injecting patients55.  
With a growing prevalence of diabetes and use of insulin therapy the lack of 
reimbursement for PNs may have costly implications.  Efforts to improve the quality of care for 
these patients should be multifaceted, incorporating increased and more frequent patient 
education, improvements in LH identification, management and monitoring, and implementation 




requires investment in both patient, caregiver and clinician education and promotion of existing 
guidelines.  
Evidence suggests that patients’ OOP costs may play a significant role in treatment 
adherence and clinical outcomes, leading to further potential medical and economic 
implications74. As saving money has been cited as a frequent reason for reusing needles, 
reimbursement of PNs may help to reduce the overall cost burden on the patient, thereby 
reducing needle reuse. This may in turn help to reduce LH associated with needle reuse.  The 
healthcare system in China has historically adopted a principle of “broad coverage, with low 
basic level of benefits”—that is, providing coverage for the greatest number of people with the 
trade-off of limited levels of benefits.  Despite the importance of PNs as a component of diabetes 
therapy, coverage of PNs has largely been overlooked.  Though a larger emphasis is usually 
placed on drugs rather than medical devices, PNs represent a necessary component for all 
diabetic patients to reliably and safely inject their insulin.  They could also have further 
implications for short term and cost containment and long-term patient outcomes. 
Study Limitations 
This study has several limitations.  First, it is cross-sectional, in which both exposures 
and outcomes are measured at a single point in time.  Therefore, although we can observe 
associations in patient characteristics and outcomes, we cannot evaluate temporal relationships or 
establish causality of these relationships.  Further work should be performed to conduct 
longitudinal analyses of these outcomes to better understand these relationships over time.  
Longitudinal research would also allow us to better understand the etiology and potential for 
resolution of LH.  Also, as this study was powered to assess prevalence of LH only, prospective 




training on correct site rotation, reduction in needle reuse and associated outcomes in patients 
with LH, to build on prior, uncontrolled work52.  
Patients’ healthcare utilization (i.e., outpatient clinic visits and hospitalization) was 
solicited in the survey via self-report over a recall period of 6 months; this longer period of time 
may introduce recall bias, in which patients may have difficulty remembering their healthcare 
utilization during this period, thus resulting in potentially inaccurate estimates of outpatient 
clinic visits and/or hospitalization.  This may be a concern more for minor types of healthcare 
utilization (e.g., outpatient clinic visits) rather than major events such as hospitalizations.  In 
tradeoff, a shorter time period would increase the risk of not being representative of patients’ 
healthcare resource utilization, especially in a chronic disease such as diabetes. 
Total healthcare costs (as opposed to resource utilization) associated with inpatient stays, 
outpatient visits and insulin use were also not directly solicited from the patient.  Therefore, 
published or private estimates of these costs from the literature or other sources of data were 
leveraged.  Actual costs may vary widely, especially since different levels of resource intensity 
may be used depending on the reason for the outpatient visit or hospital stay.  Subsequent 
research should be performed to measure actual healthcare utilization and costs for these 
patients, in order to shed further insight on the economic burden of these patients.  Furthermore, 
future studies should look at such costs in the context of total medical expenditure for this 
population to be able to account for diabetes related comorbidities that are not captured in the 
definition of diabetes related expenditure. 
Many factors can impact patients’ quality of care and outcomes.  Disease- and treatment-
related factors such as comorbidities, severity of disease, local treatment practices, 




impact patients’ outcomes.  The study did not completely control for these factors, though it did 
control for certain patient comorbidities (such as cardiovascular disease and hyperlipidemia) and 
complications of diabetes (such as retinopathy, nephropathy, neuropathy, or other complications) 
as a proxy for severity of disease.   
In order to make further recommendations on reimbursement policy, a thorough 
investigation of individual coverage policies is required.  Coverage policies for PNs in China not 
only differ by insurance type but may also vary by geographic region.  For instance, patients with 
diabetes enrolled in the UEMI in the Nanjing province pay between 5%-30% coinsurance 
(depending on age and setting of care) for PNs, whereas their counterparts in Beijing pay 100% 
of the costs for PNs OOP.  Although this study did specify PN coverage, it did not solicit 
additional information on level of coverage.  Assessment must also go well beyond PNs to 
understand the total diabetes management support that individual insurance plans offer to 
evaluate what combination of practices optimizes patient outcomes.   
Finally, the studied patient population represents those from endocrinology clinics within 
four large tertiary hospitals in China, and thus may not be representative of the entire insulin-
prescribed diabetes population in China.  Larger studies across multiple, geographically-
representative centers are needed to better understand the impact of PN reimbursement on health 
outcomes and costs nationally.  
Even considering these limitations, this research provides empirical data regarding 
characteristics of China’s insulin injecting population and healthcare cost burden for diabetic 
patients without PN reimbursement in China.  This work addresses a binary question of whether 
having some extent of PN reimbursement helps alleviate the economic burden for patients who 




further evaluate how the degree of reimbursement (i.e., percent of costs reimbursed, type of 
procedures covered) may affect the healthcare costs for this patient population, especially those 
with low income.   
Conclusions 
In conclusion, this study demonstrated that LH is common in adult, insulin-injecting 
patients in China, at four major Tier 3 medical center clinics.  It is associated with significantly 
worse glycemic control (HbA1c 0.5% greater) despite nearly one-third greater insulin 
consumption each day, compared to patients without LH.  Major risk factors appear to be 
weight-adjusted daily insulin dose and lack of proper site rotation; other factors include BMI, 
frequency of needle reuse, and lack of pen needle reimbursement.  
Insulin-dependent diabetes patients without PN reimbursement may confer a larger 
economic burden on China compared to those with PN reimbursement.  To improve outcomes 
and decrease overall costs, interventions should be considered to improve the quality of care that 
these patients receive.  Further research should focus on illustrating the reasons for 
hospitalization and increased insulin use among the non-reimbursed population.  Investigation 
should also assess the impact of variations within and between polices to identify specific areas 
for improvement.   
LH should be largely preventable by basic injection technique training to reinforce proper 
site rotation and reduction in needle reuse.  Health care professionals should inspect patients’ 
injection (and infusion) sites routinely, and provide education on proper injection technique.  
Additionally, providing increased coverage and reimbursement for PNs, along with patient 
education and increased awareness of coverage policies, may help to reduce PN reuse and 
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